Background: In LUX-Lung 8 (LL8), second-line afatinib (an irreversible ErbB family blocker) significantly improved OS (median 7.9 versus 6.8 months; HR [95% CI]: 0.81 [0.69-0.95]; p¼0.0077), and PFS (2.6 versus 1.9 months; 0.81 [0.69-0.96]; p¼0.0103) versus erlotinib in lung SCC (N¼795). Comprehensive genetic analysis in LL8 patients assessed whether afatinib efficacy varied according to genetic aberrations in cancer-related genes, including ErbB family mutations. Method: Tumor genetic analysis (TGA) was performed using Foundation Medicine FoundationOne TM next-generation sequencing (NGS). The cohort was enriched for patients with PFS >2 months, reflecting a range of responsiveness to EGFR-TKIs. EGFR expression was assessed by immunohistochemistry (IHC) in a largely separate cohort. Cox regression analysis correlated PFS/OS with genetic mutations (individual/grouped) and EGFR expression. Results: Of 440 patients selected for TGA (PFS >2 months: n¼320; 2 months: n¼120), samples from 245 were eligible (afatinib: n¼132; erlotinib: n¼113). In the selected TGA population, PFS/OS outcomes were improved in the afatinib versus erlotinib arm. Baseline characteristics were similar in TGA and IHC cohorts and LL8 overall. In the TGA subset, 53 patients (21.6%) had 1 ErbB family mutation (EGFR: 6.5%; HER2: 4.9%; HER3: 6.1%; HER4: 5.7%). Beyond the benefit seen for afatinib in the overall population, in afatinib-treated patients PFS/OS were longer when ErbB mutations were present (PFS: 4.9 versus 3.0 months; OS: 10.6 versus 8.1 months). Conversely, survival outcomes in erlotinib-treated patients were similar with/without ErbB mutations. Presence of HER2 mutations predicted favorable PFS/OS with afatinib versus erlotinib. The Table shows outcomes in patients with/ without ErbB family mutations, and by EGFR expression levels (afatinib: n¼157; erlotinib: n¼188). Conclusion: These data are provocative and suggest that NGS may enable identification of lung SCC patients who would derive additional clinical benefit from afatinib. Differential outcomes with respect to ErbB mutations for afatinib and erlotinib are hypothesized to reflect afatinib's broader mechanism of action. Clinical trial identification: NCT01523587
patients assessed whether afatinib efficacy varied according to genetic aberrations in cancer-related genes, including ErbB family mutations. Method: Tumor genetic analysis (TGA) was performed using Foundation Medicine FoundationOne TM next-generation sequencing (NGS). The cohort was enriched for patients with PFS >2 months, reflecting a range of responsiveness to EGFR-TKIs. EGFR expression was assessed by immunohistochemistry (IHC) in a largely separate cohort. Cox regression analysis correlated PFS/OS with genetic mutations (individual/grouped) and EGFR expression. Results: Of 440 patients selected for TGA (PFS >2 months: n¼320; 2 months: n¼120), samples from 245 were eligible (afatinib: n¼132; erlotinib: n¼113). In the selected TGA population, PFS/OS outcomes were improved in the afatinib versus erlotinib arm. Baseline characteristics were similar in TGA and IHC cohorts and LL8 overall. In the TGA subset, 53 patients (21.6%) had 1 ErbB family mutation (EGFR: 6.5%; HER2: 4.9%; HER3: 6.1%; HER4: 5.7%). Beyond the benefit seen for afatinib in the overall population, in afatinib-treated patients PFS/OS were longer when ErbB mutations were present (PFS: 4.9 versus 3.0 months; OS: 10.6 versus 8.1 months). Conversely, survival outcomes in erlotinib-treated patients were similar with/without ErbB mutations. Presence of HER2 mutations predicted favorable PFS/OS with afatinib versus erlotinib. The Table shows Background: Genetic alterations in the tyrosine kinase domain of EGFR are key oncogenic events in nonesmall cell lung adenocarcinoma (NSCLC). In Argentina, 15% of NSCLC patients presents EGFR mutations which direct therapy with EGFR tyrosine kinase inhibitors (TKI) at the moment of diagnosis. Nearly 50% of patients progressing to TKI have T790M resistance mutations of EGFR exon 20. This mutation is detected either in formalin fixed paraffin-embedded (FFPE) tumor tissue and cell free tumor DNA (ctDNA) in plasma (liquid biopsy). This work describes the findings in T790M evaluation in TKI progressed patients either in FFPE tumor tissue or cell free tumor DNA (ctDNA) in the first experience of liquid biopsy application for targeted therapy in Argentina. Method: NSCLC samples in either FFPE tumor tissue or ctDNA were processed from March 2017 to March 2018, from EGFR mutated patients who have radiological evidence of progression to TKI treatment. Samples were evaluated for T790M resistance mutation as requested by Oncologists or Pathologists all over the country. Due to clinical sensitivity and in case of negative results, physicians could Background: An oral ATP-competitive TKI of ALK and c-MET, Crizotinib has shown impressive clinical activity in advanced nonesmall cell lung cancers especially in the tumors harboring ALK rearrangements. With FISH as the mainstay for detection of ALK rearrangements, the ALK Break Apart FISH Probe Kit (Abbott Molecular, Des Plaines, IL) has become an FDA-approved companion diagnostic for targeted therapy with the ALK inhibitor crizotinib in lung cancers. The objective of this molecular epidemiological study is to estimate the prevalence of EML4-ALK fusion gene using IHC as a cost effective alternative to FISH for Indian patients with adenocarcinoma lung. Method: Patients with NSCLC, adenocarcinoma histology, whose tumors had been tested for EML4-ALK fusion gene using IHC were considered for this study. Permission was obtained from the Ethics committee before the start of the study. Clinical characteristics and treatment details were collected from the patient's medical records. IHC analysis was performed using a Ventana automated immunostainer (Ventana Medical Systems, Illkirch Graffenstaden, France). Detection was performed using a multimertechnology system with the UltraView Universal DAB detection kit. Results: A total of 204 NSCLC adenocarcinoma patients were included in the study. There were 126 (61.7%) men and 78 (38.23%) women with a median age of 57 years. Of the 204 patients, 47 (23.03%) were non-smokers and 175 (85.78%) had stage-IV disease at the time of initial diagnosis. 48 (23.52%) blocks were positive for EGFR mutations whereas 156 (76.47%) were EGFR wild type. EML4-ALK fusion gene was present in 27 (13.23%) patients whereas 177 (86.76%) tumors were EML4-ALK negative. 25 out of the 27 patients with ALK positivity received Crizotinib therapy. Conclusion: The incidence of EML4-ALK gene fusions (13.23%) in this Indian population is four fold high than the previous reported incidences and supports the claim of several recent studies that a relatively new ALK clone, 5A4 and D5F3 from cell signaling technology (Ventana) can accurately identify ALK rearranged lung ACA as compared to FISH. The inclusion of IHC for the detection of EML4-ALK gene fusions as a low cost alternative seems warranted. Keyword: EML4-ALK Immuno histo chemistry. Crizotinib was the first ALK TKI approved in the first line setting, after showing superiority over chemotherapy Method: We retrospectively reviewed the medical records of patients with ALK positive lung cancer from February 2014 to May 2018. The objective was to describe the incidence, clinical and pathological characteristic, and to determine the progression free survival in the patients that received first-line crizotinib Results: There were 406 patients diagnosed with lung cancer and 26 of the cases were ALK positive, representing 6,4%. The mean age of diagnosis is 64 years (37 e 85) and 53,1% of patients were females. 92,4% of the patients had PS between 0 e 2. 43,2% of the patients were smokers. All patients were diagnosed with at least locally advanced disease and 73,1% had stage IV disease. At baseline, 2 patients had SNC metastasis (10,3%). 20 patients received first line therapy with crizotinib. Conclusion: The median progression free survival 10.9 months (95% IC 7.69 e 14.12) with first line crizotinib at our institution is similar to pivotals trials. Background: The neutrophil to lymphocyte ratio (NLR) has been used as systemic inflammation marker and related to worse prognosis in both, neoplastic and non-neoplastic diseases. Several studies in surgically treated lung cancer patients have shown the correlation between NLR and survival using 5 as the cut-off. However, its value in metastatic disease has been little investigated. The aim of this study was to explore the correlation between NLR (cut-off of 5) and overall survival
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